<DOC>
	<DOCNO>NCT00002173</DOCNO>
	<brief_summary>To provide alternative therapy HIV-infected patient comparable satisfactory alternative drug therapy available .</brief_summary>
	<brief_title>An Expanded Access Open Label Protocol Remune ( HIV-1 Immunogen ) HIV-1-Infected Adults With CD4 Count 550 Cells /Ml Greater .</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV1 seropositivity . CD4 count &gt; = 550 cells/ml . NOTE : If patient 's CD4 count 550 600 cells/ml , patient must either rescreen within 30 day Study 806 wait 6 month enter expanded access program . Patient must fail intolerant comparable alternative market therapy must candidate therapy . Patient must meet inclusion criterion Remune trial . Patient must laboratory test within specify limit . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Clinically significant cardiac , hepatic , renal gastrointestinal dysfunction . Current participation Remune study . Concurrent Medication : Excluded : Use immunemodulating drug . Induction therapy initiation new treatment regimen AIDSdefining condition . Current participation Remune study . Patients follow prior condition exclude : Previous participation Remune study . Prior Medication : Excluded : Previous participation Remune study . Excluded within 30 day study entry : Use immunemodulating drug . Induction therapy initiation new treatment regimen AIDSdefining condition within 30 day Day 1 visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1998</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>CD4 Lymphocyte Count</keyword>
	<keyword>Salk HIV Immunogen</keyword>
</DOC>